

Ref: FOI/GS/ID 8835

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

27 February 2024

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Breast Cancer.

You asked: All questions are shown as received by the Trust.

- 1) *In the past 3 months, how many advanced/metastatic breast cancer patients have the status of;*
- a) *HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]*
 - b) *HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]*
 - c) *The total number of Metastatic breast cancer patients of any type.*
- 2) *In the past 3 months, how many metastatic breast cancer patients were treated with:*
- a) *Trastuzumab + Pertuzumab + paclitaxel*
 - b) *Trastuzumab + paclitaxel Trastuzumab as a single agent*
 - c) *Trastuzumab emtansine*
 - d) *Trastuzumab Deruxtecan*
 - e) *Tucatinib + Trastuzumab + Capecitabine*

Trust response:

Results below for period 1/10/2023- 31/12/2023

- 1)
a) 0
b) 0
c) 0
- 2)
- | | |
|--|---|
| a) Trastuzumab + Pertuzumab + paclitaxel | 0 |
| b) Trastuzumab + paclitaxel Trastuzumab as a single agent | 0 |
| c) Trastuzumab emtansine | 1 |

- d) Trastuzumab Deruxtecan 0
- e) Tucatinib + Trastuzumab + Capecitabine 0
- f) **Trastuzumab as a single agent** 4

We have shown Trastuzumab as a single agent separately as b) seemed to combine two distinct items.